Therefore, identification of SMRT as a downstream target of ErbB2 that plays a critical role in transcriptional regulation will help develop therapeutic agents for ErbB2-positive cancer patients, such as screening small molecule(s) that increase SMRT protein levels. Here, NCOR2 is linked to cancer.